drugset / Trial / NCT03516045

A Study of 18F-AlF-NOTA-Neurotensin PET/CT for Imaging Prostate Cancer

NCT03516045 ↗

Phase 1/2 Unknown 65 enrolled Xiangya Hospital of Central South University
NaSingle-groupOpen-labelDiagnostic

Summary

The aim of this study is to investigate the clinical value of \[18F\]aluminum fluoride-1,4,7-triazacyclononane-1,4,7-triacetic acid-neurotensin(18F-AlF-NOTA-neurotensin)positron emission tomography / computed tomography (PET/CT) in patients with prostate cancer (PCa).

Timeline

Start
2018-04-23
Primary completion
2019-12-30
Completion
2020-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject 18F-AlF-NOTA-neurotensin Diagnostic / imaging agent — —

Indications